8. פפססווררייאאזזייסס::
ההששפפעעוותת
ייחחססייוותת ששלל
""טטררייגגררייםם""
ממווככררייםם::
החמרה לא ברור שיפור
=100%
פציעה
מזג אויר קר
מזג אויר חם
שמש
אלכוהול
מתח נפשי
עליה/עודף משקל
זיהומי נשימה
הריון
21. S F - 3 6 H E A L T H S U R V E Y
IImmppaacctt ooff PPssoorriiaassiiss vvss OOtthheerr DDiisseeaasseess
oonn PPaattiieenntt--RReeppoorrtteedd PPhhyyssiiccaall OOuuttccoommeess
Congestive Heart Failure 35
Psoriasis 41
Diabetes
Chronic Lung Disease
Myocardial Infarction
42
42
43
Arthritis 43
Hypertension 44
Depression 45
Cancer 45
0 5 10 15 20 25 30 35 40 45 50
Physical Component Summary Score (n=317)
Lower scores reflect worse patient-reported outcomes.
SF-36 Score
Rapp SR, et al. J Am Acad Dermatol. 1999;41:401-407.
Ware JE Jr, et al. SF-36® Health Survey Manual and Interpretation Guide. The Health Institute; 1993.
22. IImmppaacctt ooff PPssoorriiaassiiss vvss OOtthheerr DDiisseeaasseess oonn
PPaattiieenntt--RReeppoorrtteedd MMeennttaall OOuuttccoommeess
Depression 35
46
49
49
Arthritis
Congestive Heart Failure 50
0 10 20 30 40 60
Mental Component Summary Score (n=317)
Psoriasis
Cancer
Rapp SR, et al. J Am Acad Dermatol. 1999;41:401-407.
S F - 3 6 H E A L T H S U R V E Y
Lower scores reflect worse patient-reported outcomes.
SF-36 Score
Chronic Lung Disease 44
Diabetes 52
Hypertension 52
Myocardial Infarction 52
50
49. פפססווררייאאזזייסס –– טטייפפווללייםם ""בבייווללווגגייייםם"" ""חחדדששייםם""
BBiioollooggiiccaall tthheerraappiieess ffoorr ppssoorriiaassiiss && ppssoorriiaattiicc aarrtthhrriittiiss
Agent Agent type Clinical stage
Infliximab )Remicade( anti TNF mc-Ab Approved for Pso
Approved for PA
Adalimumab )Humira( anti TNF mc-Ab In phase IV trial for Pso
Approved for PA
Etanercept )Enbrel( Soluble TNF receptor FDA & EMEA approved for Pso
FDA & EMEA approved for PA
Efalizumab )Raptiva( T-cell modulator FDA & EMEA approved for Pso
Failed in PA
Alefacept )amevive( T-cell modulator FDA & IMH approved for Pso
- “ - With MTX In phase II trial for PA
50. ההששוווואאהה ששלל ייחחסס עעללוותת//ייעעייללוותת ששלל
ההבבייווללווגגייייםם ללטטייפפוולל ששלל 1122 ששבב''
Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy
measures assessed over a 12-week treatment period. Nelson AA etal, J Am Acad Dermatol. 2007 Nov 7
68. Clinical images of a patient with a good response (Psoriasis Area Severity Index [PASI] reduction
>= 50%) on both UV-irradiated and nonirradiated body sides (A-C) and of a patient with no
response on the nonirradiated body side but complete response (PASI reduction to <= 3) on the
Copyright restrictions may apply.
UV-irradiated side (D-F)
Legat, F. J. et al. Arch Dermatol 2007;143:1016-1022.